incretin hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Alpha particles were first described in the investigations of radioactivity by Ernest Rutherford in 1899, and by 1907 they were identified as He2+ ions. By 1928, George Gamow had solved the theory of alpha decay via tunneling. The alpha particle is trapped inside the nucleus by an attractive nuclear potential well and a repulsive electromagnetic potential barrier. Classically, it is forbidden to escape, but according to the (then) newly discovered principles of quantum mechanics, it has a tiny (but non-zero) probability of "tunneling" through the barrier and appearing on the other side to escape the nucleus. Gamow solved a model potential for the nucleus and derived, from first principles, a relationship between the half-life of the decay, and the energy of the emission, which had been previously discovered empirically and was known as the Geiger–Nuttall law.
==== Social Democratic Party of Germany ==== At the first party conference of the re-established SPD, held in Leipzig from 22 to 25 February 1990, the party adopted its basic programme and election manifesto centred on the promotion of an ecologically oriented social market economy.
DCPIP (blue) + H+ → DCPIPH (pink) DCPIPH (pink) + vitamin C → DCPIPH2 (colorless) In this titration, when all the ascorbic acid in the solution has been used up, there will not be any electrons available to reduce the DCPIPH and the solution remains pink due to the DCPIPH. The end point is a pink color that persists for 10 seconds or more, if there is not enough ascorbic acid to reduce all of the DCPIPH. Pharmacological experiments suggest that DCPIP may serve as a pro-oxidant chemotherapeutic targeting human cancer cells in an animal model of human melanoma; DCPIP-induced cancer cell death occurs by depletion of intracellular glutathione and upregulation of oxidative stress.
Sources: en.wikipedia.org
== Veterinary use == Cyproheptadine is used in cats as an appetite stimulant and as an adjunct in the treatment of asthma. Possible adverse effects include excitement and aggressive behavior. The elimination half-life of cyproheptadine in cats is 12 hours. Cyproheptadine is a second line treatment for pituitary pars intermedia dysfunction in horses.
24 November Promising results of therapeutic candidates are reported:a universal flu mRNA vaccine, a phase 3 trialed RSV vaccine (1 Nov), phase 3 trialed antibiotic gepotidacin against UTIs (3 Nov), phase I trialed new antibiotic for gram-negative bacteria QPX9003 (20 Oct/9 Nov), phase 2 trialed antibody CIS43LS against malaria (17 Nov), phase 2 trialed acoziborole against African sleeping sickness parasites (29 Nov), and phase 3 trialed lecanemab against Alzheimer's disease (29 Nov). A new CRISPR-Cas9 gene editing tool for large edits without problematic double-stranded breaks is demonstrated, PASTE. 29 November Canadian mineralogists discover two new minerals, Elkinstantonite and Elaliite, on the 15-tonne El Ali meteorite that grounded in Somalia. A study maps common disease combinations or multimorbidity patterns, a "growing public health problem worldwide". 30 November An electrolysis system for viable hydrogen production from seawater without requiring a pre-desalination process, which could make it less flexible and more costly, is reported. A study deploying protein imaging of adult mice suggests adult brains contain, at the tips of filopodia, many (~30% of all dendritic protrusions) "silent synapses" that are inactive until recruited as part of neural plasticity and flexible learning or memories, previously thought to be present mainly in the developing pre-adult brain and to die off with time.
== People == C4 (rapper), a rap music producer from Birmingham, England Clarence Mitchell IV, American radio host and former politician Chris Turner, sometimes credited as Chris Heiner, a.k.a. "C4", Australian musician, part of Modern Day Poets
=== Vishal Y Joshi's method === Joshi et al. (2006) propose the Koenigs-Knorr reaction in the stereoselective synthesis of alkyl D-glucopyranosides via glycosylation, with the exception of using lithium carbonate which is less expensive and toxic than the conventional method of using silver or mercury salts. D-glucose is first protected by forming the peracetate by addition of acetic anhydride in acetic acid, and then addition of hydrogen bromide which brominates at the 5-position. On addition of the alcohol ROH and lithium carbonate, the OR replaces the bromine and on deprotecting the acetylated hydroxyls the product is synthesized in relatively high purity. It was suggested by Joshi et al. (2001) that lithium acts as the nucleophile that attacks the carbon at the 5-position and through a transition state the alcohol is substituted for the bromine group. Advantages of this method as well as its stereoselectivity and low cost of the lithium salt include that it can be done at room temperature and its yield compares relatively well with the conventional Koenigs-Knorr method.
Sources: en.wikipedia.org
==== Actions ==== RO5073012 has high affinity for the mouse, rat, cynomolgus monkey, and human TAAR1 (Ki = 0.5–6 nM), is highly potent and selective as an agonist of the TAAR1 of these species (EC50Tooltip half-maximal effective concentration = 8.8–25 nM), and has relatively low intrinsic activity at the TAAR1 of these species (EmaxTooltip maximal efficacy = 24–43% relative to β-phenethylamine).
Bagwell set the record for the fewest plate appearances in a season reaching 100 of both runs scored and runs driven in and became the first National Leaguer to finish first or second in batting average, home runs, RBI, and runs scored since Willie Mays in 1955. His .750 SLG at the time ranked as the seventh-best ever and was the highest by a National Leaguer since Rogers Hornsby in 1925 (.756). Further, at the time in National League history, the 213 OPS+ trailed only Hornsby's 1924 season (222 OPS+) for the second-highest ever. The 116 RBI in 110 games qualified for the 13th-highest ratio in history. He also hit 23 home runs in 56 games at the Astrodome, setting a record that stood for the stadium that was famed to be pitcher-friendly until the Astros moved out following the 1999 season. He set single-season club records for batting average, SLG, OPS, OPS+, AB/HR, and offensive win percentage (.858), as well as home runs, breaking Wynn's 27-year-old record, and RBI, breaking Bob Watson's record 17 years earlier. Bagwell broke the team home run and RBI records later in his career. The unanimous winner of the NL Most Valuable Player Award, he became the fourth player in National League history to win by this distinction, and the first Astros player to win the award. Bagwell also won his first Silver Slugger, Gold Glove, and Player of the Year Awards from The Sporting News, Associated Press, Baseball Digest, and USA Today Baseball Weekly. "Crazy stuff happened that year", Bagwell recalled of his 1994 season. "Every pitch that I was looking for, I got.
The death of his brother-in-law, John Gardner, from tetanus led to an interest in treating the disease, which he pursued in collaboration with Paul Fildes and H. E. Harding. He also researched the structure and function of the lymphatic system with Pullinger, and continued his studies of contraception with Harry Carleton that had begun at London Hospital. Florey's son Charles du Vé was born in Sheffield on 11 September 1934, but for a time Florey's relationship with Ethel had deteriorated to the point where they were communicating in writing and contemplating a legal separation. This was regarded as a serious matter; no Oxford fellow divorced without resigning his fellowship until the 1950s.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.